TVTX
Travere Therapeutics, Inc.
November 3, 2026 · pre-market
- Rarity
- 2.06
- Peak move
- −8.80%
- Float cap
- $4.4B
Still running — rarity and peak move can only rise from here.
Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers therapies for people with rare kidney and metabolic diseases. It commercializes FILSPARI (sparsentan) for adults with primary IgAN at risk of disease progression, and is developing sparsentan for FSGS and pegtibatinase for HCU.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNot searched yet.A blank here does not mean there was no cause.